The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...
Preclinical results were recently presented from studies conducted by Fulcrum Therapeutics Inc. evaluating FTX-6274, a novel, orally bioavailable embryonic ectoderm development (EED) inhibitor that ...
Verywell Health on MSN
Understanding metastatic castration-resistant prostate cancer
Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Metastatic castration-resistant prostate cancer is an advanced form ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback